Domestic drugs take the lead
According to the South China Morning Post, China’s Ministry of Industry and Information Technology said at a press conference in Beijing on Tuesday, October 20, that domestic innovative drugs accounted for 80% of all innovative medicines approved in the first three quarters.
Research progress has been made across multiple therapeutic areas including oncology, psychiatry, anti-infectives, gout and rare diseases.
According to the National Development and Reform Commission, China’s innovative drug out-licensing deals reached about US$130 billion by the end of September, nearly matching the full-year level of 2025, showing the growing appeal of Chinese pharmaceutical assets to international groups.
A new deal between Hansoh and Roche
Hong Kong-listed Hansoh Pharmaceutical Group said three of its subsidiaries had reached a collaboration agreement with Switzerland’s F. Hoffmann-La Roche covering a broad portfolio of antibody-drug conjugate (ADC) programmes. It is the second collaboration between the two sides. Key terms include:
















